Lam Research
LRCX
$221.31
+10.41%
Lam Research is one of the world's largest semiconductor wafer fabrication equipment manufacturers, specializing in deposition and etch processes that build up and selectively remove material layers on a chip, serving memory and logic customers including TSMC, Samsung, Intel, and Micron. It holds the top market share in etch and a clear second position in deposition, giving it a critical chokepoint role in advanced-node manufacturing and a distinct competitive identity as a high-margin, memory-levered process-equipment specialist rather than a broad-line platform vendor. The current investor narrative centers on AI-driven semiconductor complexity, with record quarterly results and raised long-term targets cited in recent coverage, alongside speculation about whether Lam could eventually become a trillion-dollar company. That bullish framing is now colliding with a sharp late-2026 drawdown, as the stock has fallen roughly 39% in a month despite strong fundamentals, reviving debate over whether the selloff is a valuation reset or an early signal of a memory capex slowdown.…
LRCX
Lam Research
$221.31
Related headlines
Investment Opinion: Should I buy LRCX Today?
Rating: Buy (accumulate, scaled entry). The core thesis is that Lam's fundamentals and its stock price have decoupled: revenue grew 54.38% YoY to $8.22 billion in the September 2026 quarter with gross margin expanding to 52.3%, yet the shares trade at $200.44, roughly 45% below the $364.03 average analyst target and 32% above the $135.50 52-week low. With 30 Buy ratings, 4 Holds, zero Sells, and a recommendation mean of 1.38, the consensus is strong_buy, and even the lowest target of $255.00 implies about 27% upside, so the analyst community views the -39.17% one-month collapse as a dislocation rather than a fundamental break.
Supporting evidence is unusually concrete for a stock this beaten down. The primary valuation metric is the forward PE of 16.38x against consensus EPS of $18.67, versus a trailing PE of 70.97x, a roughly 77% compression that prices in the earnings ramp rather than requiring it to be discovered. Revenue has compounded sequentially from $5.34B to $5.84B to $6.72B to $8.22B over four quarters, gross margin has climbed from 49.6% to 52.3%, and net margin reached 33.50% with ROE of 58.26%. Free cash flow of $6.54 billion TTM covers $257.7 million of capex, $325.4 million of dividends, and $1.02 billion of buybacks, while debt-to-equity of 0.33 and a current ratio of 2.63 mean the balance sheet is not the constraint. The premium multiples (22.20x sales, 41.35x book, 59.08x EV/EBITDA) are the bear's best argument, but they sit alongside a 1.83 PEG and a forward multiple near the low end of the stock's historical band.
Three risks could invalidate the thesis: a memory capex pause at Samsung or Micron that cuts the $18.67 consensus EPS, a continued momentum breakdown below the $185 support that held on November 5, and multiple compression driven by the 2.01 beta in a sector rotation. The rating would upgrade to a higher-conviction Buy if the stock reclaims the $230-$250 breakdown zone while estimates hold, and would downgrade to Hold if forward EPS estimates fall more than 15% or the shares close decisively below $185. On balance the stock is undervalued on forward earnings and overvalued on trailing metrics, a split that resolves only when the next quarter confirms or denies the $8.22 billion run-rate.
Sign up to view all
LRCX 12-Month Price Forecast
The forward-looking case rests on a simple asymmetry: the market has priced a memory capex slowdown that has not appeared in any reported number, with revenue up 54.38% and margins expanding sequentially through the September quarter. At 16.38x forward earnings against a $364.03 average target, the downside to the $135.50 52-week low is roughly 32% while the upside to consensus is about 82%, a favorable ratio even after weighting the 20% bear probability. The offsetting evidence is real: a -39.17% one-month decline, -34.18 relative strength versus SPY, and a 2.01 beta mean the tape is broken, and the analyst community has not yet revised targets, so the 81.6% gap could be stale rather than opportunity. I would upgrade to high confidence if the next quarter confirms revenue at or above $8.22 billion with gross margin above 52%, and downgrade to neutral if consensus EPS of $18.67 is cut by more than 15% or the stock closes decisively below $185.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Lam Research's 12-month outlook, with a consensus price target around $363.03 and implied upside of +64.0% versus the current price.
Average Target
$363.03
34 analysts
Implied Upside
+64.0%
vs. current price
Analyst Count
34
covering this stock
Price Range
$255 - $500
Analyst target range
Coverage is deep and overwhelmingly bullish, with 30 analysts contributing 30 Buy ratings, 4 Holds, and zero Sells, yielding a consensus recommendation of strong_buy and a recommendation mean of 1.38. The average target price of $364.03 implies roughly 81.6% upside from the current $200.44, a gap that reflects how far the stock has fallen below the analyst community's fair-value estimates rather than any recent downgrade cycle. The consensus clearly leans bullish, and the estimated average EPS of $18.67 and average revenue of $60.28 billion underpin that optimism. The target range is wide, from a low of $255.00 to a high of $500.00, signaling meaningful dispersion in conviction. The high target assumes multiple expansion and sustained AI-driven growth toward the trillion-dollar narrative, while even the low target of $255.00 sits about 27% above the current price, implying analysts view the selloff as overdone. Institutional ratings show a pattern of reaffirmations rather than downgrades, with UBS, Mizuho, Citigroup, Needham, Morgan Stanley, and Evercore ISI all maintaining Buy or Outperform ratings through October 2026, suggesting the recent price collapse has not yet been reflected in formal target revisions and that the spread between price and targets may narrow through either a rebound or a wave of cuts.
Bulls vs Bears: LRCX Investment Factors
The evidence currently favors the bull side, but narrowly and with a critical caveat: fundamentals are unambiguously strong while price action is unambiguously broken. Revenue growth of 54.38%, gross margin expansion to 52.3%, $6.54 billion of TTM free cash flow, and a 0.33 debt-to-equity ratio describe a company firing on all cylinders, and a forward PE of 16.38x against a $364.03 average target implies the market has priced in a slowdown that has not appeared in the numbers. Against that, a -39.17% one-month collapse, -34.18 relative strength versus SPY, and a beta of 2.01 mean the market is voting with its feet, and the analyst community has not yet revised targets downward, leaving the 81.6% upside gap potentially stale. The single most important tension is whether the selloff is a valuation reset or an early signal of memory capex deceleration; if the next quarter confirms the $8.22 billion revenue run-rate, the bull case wins decisively, but if orders soften, the 16.38x forward multiple is built on estimates that will fall.
Bullish
- Revenue accelerating at 54% YoY: September-quarter revenue hit $8.22 billion, up 54.38% year-over-year, with a sequential ramp from $5.34B to $5.84B to $6.72B to $8.22B over four quarters. This is compounding growth, not a plateau, and it directly contradicts the bear case that the selloff is an early memory-capex slowdown signal.
- Margins expanding through the cycle: Gross margin climbed sequentially from 49.6% to 49.8% to 51.7% to 52.3%, while operating margin reached 39.95% and net margin 33.50%. That pricing power and mix improvement is unusual for capital-equipment makers and supports a structurally higher earnings base than the trailing multiple implies.
- Forward PE of 16.4x is value-like: The trailing PE of 70.97x collapses to a forward PE of 16.38x against consensus EPS of $18.67, a roughly 77% compression. The de-rating has already discounted much of the near-term growth, leaving the stock cheap on forward earnings if AI capex holds.
- Analyst consensus strong buy, 82% upside: 30 Buy ratings, 4 Holds, and zero Sells yield a recommendation mean of 1.38, with an average target of $364.03 implying 81.6% upside from $200.44. Even the low target of $255.00 sits about 27% above the current price, and UBS, Mizuho, Citigroup, Needham, Morgan Stanley, and Evercore all reaffirmed Buy through October 2026.
Bearish
- Falling knife: -39% in one month: The stock is down 39.17% over one month and 35.62% over three months against a 1-year gain of 23.58%, a clear trend reversal rather than a healthy pullback. At $200.44 it sits at just 21.4% of its $135.50-$438.50 range, with a max drawdown of -57.26%.
- Severe relative strength deterioration: One-month relative strength versus SPY is -34.18 and three-month is -30.71, meaning Lam has lost 30-34 percentage points to the index in each window. The 6-month change of -31.83% shows a sustained de-rating, not a one-off shock.
- Trailing valuation far above history: The 70.97x trailing PE is well above the stock's historical 9x-35x band, and the 22.20x PS ratio compares with 10x-12x readings in 2022. EV/EBITDA of 59.08x and price-to-book of 41.35x confirm premium positioning that leaves little margin for error.
- Beta of 2.01 amplifies drawdowns: At roughly twice the market's volatility, a 2.01 beta means macro or sector rotation shocks hit Lam disproportionately. The short ratio of 3.15 shows bears remain positioned for further weakness, and the 8.23% single-day bounce from $185.20 is one session, not a reversal.
LRCX Technical Analysis
Lam Research is in a violent correction within a still-positive longer-term trend: the stock is up 23.58% over the past year and 8.31% year-to-date, but the current price of $200.44 sits at just 21.4% of its 52-week range of $135.50 to $438.50, having collapsed from a peak near $438.50 in late June. That positioning near the bottom of the range, with a maximum drawdown of -57.26%, indicates a falling-knife setup rather than a healthy pullback, even though the 1-year return remains positive. The 8.23% single-day bounce on the latest close (from $185.20 to $200.44) suggests buyers are attempting to defend the $185-$200 zone, but one session does not reverse a downtrend of this magnitude. Short-term momentum is decisively negative and decelerating sharply: the stock is down 39.17% over one month and 35.62% over three months, versus a 1-year gain of 23.58%, a clear divergence that signals trend reversal rather than mean reversion. Relative strength confirms the underperformance, with a 1-month relative strength of -34.18 and a 3-month figure of -30.71 against SPY, meaning Lam has lost roughly 30-34 percentage points to the index in each window. The 6-month change of -31.83% shows the deterioration is not a one-off shock but a sustained de-rating, and the elevated short ratio of 3.15 suggests bears remain positioned for further weakness. Key levels are well defined: support sits at the 52-week low of $135.50, roughly 32% below the current price, while resistance begins at the $230-$250 area where the October breakdown accelerated and extends to the $438.50 high. A breakout above $250 would suggest the capitulation low is in, whereas a breakdown below $185 would open the path toward the $135.50 floor. With a beta of 2.01, the stock is roughly twice as volatile as the market, so position sizing should assume drawdowns of this scale are normal rather than anomalous.
Beta
2.01
2.01x market volatility
Max Drawdown
-57.3%
Largest decline past year
52-Week Range
$136-$439
Price range past year
Annual Return
+38.9%
Cumulative gain past year
| Period | LRCX Return | S&P 500 |
|---|---|---|
| 1m | -30.6% | -3.3% |
| 3m | -28.9% | -2.3% |
| 6m | -25.1% | +1.4% |
| 1y | +38.9% | +12.2% |
| ytd | +19.6% | +10.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LRCX Fundamental Analysis
Revenue is accelerating powerfully, not decelerating: the most recent quarter (ended September 27, 2026) delivered $8.22 billion in revenue, up 54.38% year-over-year, and the sequential progression from $5.34 billion to $5.84 billion to $6.72 billion to $8.22 billion over four quarters shows compounding growth rather than a plateau. Systems revenue of $5.73 billion and Customer Support and Other revenue of $2.49 billion indicate the growth is led by tool shipments while the installed-base service stream provides a recurring ballast. This trajectory, reinforced by raised long-term targets tied to AI-driven process complexity, supports a structurally higher earnings base than the stock's current multiple implies. Profitability is exceptional and expanding: net income reached $2.75 billion in the latest quarter on a 52.3% gross margin, up from $1.59 billion and a 49.6% gross margin in the year-ago quarter, with the operating margin climbing to 39.95% and net margin to 33.50%. Gross margin has risen sequentially from 49.6% to 49.8% to 51.7% to 52.3%, a clear expansion trend driven by mix and pricing power, and the 35.29% operating margin and 31.27% net margin are well above what is typical for capital-equipment manufacturers. The balance sheet is conservatively managed, with debt-to-equity of just 0.33, a current ratio of 2.63, and $7.45 billion of cash at period end. Free cash flow is robust at $6.54 billion TTM and $3.24 billion in the latest quarter alone, comfortably covering $257.7 million of capex, $325.4 million of dividends, and $1.02 billion of buybacks, while ROE of 58.26% and ROA of 25.01% reflect a highly capital-efficient model that funds growth internally rather than relying on external financing.
Quarterly Revenue
$8.2B
2026-09
Revenue YoY Growth
+54.4%
YoY Comparison
Gross Margin
52.3%
Latest Quarter
Free Cash Flow
$6.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LRCX Overvalued?
Because net income is positive ($2.75 billion in the latest quarter), the PE ratio is the appropriate primary metric, and the trailing PE of 70.97x stands in stark contrast to the forward PE of 16.38x. That roughly 77% compression implies the market expects earnings to multiply, consistent with consensus EPS estimates of $18.67 versus the current trailing figure, and it frames the stock as optically expensive on history but inexpensive on forward earnings if the AI capex cycle holds. On peer comparison, the 22.20x PS ratio and 9.44x EV/Sales sit well above typical semiconductor-equipment norms, and the 41.35x price-to-book and 88.04x price-to-cash-flow multiples confirm a premium positioning. That premium is partly justified by a 52.3% gross margin, 33.5% net margin, and 58.3% ROE that exceed most peers, but the 59.08x EV/EBITDA and 1.83 PEG ratio suggest the market is already pricing in substantial growth, leaving limited margin for error. Against its own history, the stock is near the top of its valuation band: the PE ratio has ranged from roughly 9x-35x over the past several years, and the current 70.97x trailing figure is far above that range, while the PS ratio of 22.20x compares with historical readings as low as 10x-12x in 2022. The forward PE of 16.38x, however, is near the low end of the historical band, meaning the de-rating has already discounted much of the near-term earnings growth. The tension is that the market is pricing optimistic AI-driven expectations on trailing metrics while offering a value-like multiple on forward numbers, so the stock's direction now hinges on whether estimates of $18.67 EPS prove durable.
PE
71.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 9x~36x
vs. Industry Avg
54.4x
Industry PE ~54.4x*
EV/EBITDA
59.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on estimate dependence rather than balance-sheet stress. The 70.97x trailing PE only works because consensus EPS of $18.67 is expected to multiply earnings, and the 16.38x forward multiple is a trap if that number slips; a 20% cut to estimates would push the forward PE back above 20x at today's price. Revenue is heavily levered to memory customers for DRAM and NAND, so a single capex pause at Samsung or Micron could hit the $5.73 billion systems revenue line quickly, and the 54.38% YoY growth rate is precisely the kind of figure that mean-reverts hardest. Free cash flow of $6.54 billion TTM and a 0.33 debt-to-equity ratio provide real cushion, but they do not protect the multiple if the growth narrative breaks. Market and competitive risks are dominated by valuation compression and volatility. At 22.20x sales, 41.35x book, and 59.08x EV/EBITDA, Lam trades at a premium to typical semiconductor-equipment norms, and the stock's own history shows a 9x-35x PE band and 10x-12x PS readings in 2022, meaning a full normalization would be brutal. A beta of 2.01 makes the shares roughly twice as sensitive to macro shocks, and the -34.18 one-month relative strength versus SPY shows sector rotation is already underway; the July 2026 'sell the news' reaction to Samsung's strong earnings is a template for how good news can still pressure AI-linked semis. Competition in etch and deposition from Applied Materials and others, plus any export-control tightening, adds a regulatory layer that could cap the multiple regardless of fundamentals. The worst-case scenario is a memory capex cut coinciding with estimate revisions and multiple compression. If DRAM and NAND makers trim spending, consensus EPS of $18.67 falls, analysts cut the $364.03 average target, and the stock retests its 52-week low of $135.50, roughly 32% below the current $200.44. A break below the $185 support that held on November 5 would open that path directly, and the -57.26% max drawdown shows losses of this scale are within the stock's normal behavior; from today's price, a move to $135.50 represents about -32%, and a repeat of the full drawdown from the $438.50 peak would be far worse for anyone who bought near the high.
FAQ
The most severe risk is estimate dependence: the entire bull case rests on consensus EPS of $18.67, and a 20% cut would push the forward PE back above 20x at today's price, instantly erasing the value argument. Second is memory concentration, since Lam is more exposed to DRAM and NAND capex than broad-line peers, and a spending pause at Samsung or Micron would hit the $5.73 billion systems revenue line faster than the 54.38% growth rate suggests. Third is valuation compression: at 22.20x sales and 41.35x book, a normalization toward historical norms would be painful regardless of fundamentals, and the July 2026 'sell the news' reaction to Samsung's strong earnings shows good news can still pressure AI-linked semis. Fourth is volatility and momentum, with a 2.01 beta roughly doubling market moves, a -34.18 one-month relative strength versus SPY, and a short ratio of 3.15 indicating bears remain positioned for further weakness. Balance-sheet risk is the least concerning, with debt-to-equity of 0.33, a current ratio of 2.63, and $6.54 billion of TTM free cash flow.
The scenario framework assigns a 50% probability to the base case of $255-$364, a 30% probability to the bull case of $364-$500, and a 20% probability to the bear case of $135.50-$255. The base case assumes the selloff is a valuation reset rather than a demand signal, with the $18.67 consensus EPS holding within a 5% band, gross margin staying in the 51%-53% range, and the stock grinding back toward the $255 low target first and the $364.03 average as the ceiling. The bull case requires the $8.22 billion revenue run-rate to prove durable with gross margin above 52%, plus memory capex guidance increases and formal target revisions toward the $364-$500 range. The bear case is a memory capex pause that forces estimate cuts and a retest of the $135.50 low, a roughly 32% decline from $200.44. The base case is most likely because the reported numbers have not yet shown any demand deterioration, but the key assumption is that estimates hold through the next two reporting cycles.
The answer depends entirely on which multiple you anchor to, and that split is the heart of the debate. On trailing metrics the stock is expensive: 70.97x PE, 22.20x sales, 41.35x book, 59.08x EV/EBITDA, and 88.04x price-to-cash-flow all sit at or above the top of the stock's historical band, versus PE readings of roughly 9x-35x and PS readings of 10x-12x in 2022. On forward numbers it looks cheap: the 16.38x forward PE against consensus EPS of $18.67 represents roughly 77% compression from the trailing figure and sits near the low end of the historical range. The market is therefore paying a premium for proven current profitability while discounting the forward earnings ramp, which means the valuation implies the market expects either a memory capex slowdown or estimate cuts. If the $18.67 EPS estimate holds, the stock is undervalued on forward earnings; if estimates fall 20%, the forward multiple jumps back above 20x and the apparent discount disappears.
The risk/reward is favorable but not one-sided. At $200.44, the stock sits 81.6% below the $364.03 average analyst target and even the lowest target of $255.00 implies about 27% upside, while the downside to the $135.50 52-week low is roughly 32%, a ratio that favors buyers with patience. The fundamental backdrop supports that asymmetry: revenue grew 54.38% YoY to $8.22 billion, gross margin expanded to 52.3%, and the forward PE of 16.38x is value-like against consensus EPS of $18.67. The catch is that the tape is broken, with a -39.17% one-month decline, -34.18 relative strength versus SPY, and a 2.01 beta, and the analyst targets have not yet been revised, so the upside gap could be stale rather than opportunity. It is a good buy for long-horizon investors who can scale in and tolerate a retest of $185 or even $135.50, but it is a poor vehicle for anyone needing near-term stability or income, given the 0.25% dividend yield.
This is a long-term holding, not a trading vehicle, despite the temptation created by the recent volatility. The growth stage is mature-cyclical rather than early-stage: revenue is already $8.22 billion per quarter and the market cap is roughly $285 billion, so the upside comes from AI-driven process complexity and earnings compounding rather than from a small-cap re-rating. The 2.01 beta and -57.26% max drawdown mean short-term holders face violent swings, and the 0.25% dividend yield with a 17.5% payout ratio provides essentially no income cushion while waiting. Earnings visibility is decent but not high, since results hinge on customer capex budgets at Samsung, Micron, TSMC, and Intel that are set annually and can shift quickly. A minimum holding period of 18-24 months is appropriate, long enough to span at least two memory capex cycles and allow the forward earnings ramp implied by the 16.38x forward PE to materialize or be disproven.